CSL (CSLLY) Issuance of Debt : $807 Mil (TTM As of Dec. 2023)

View and export this data going back to 2008. Start your Free Trial

What is CSL Issuance of Debt?

CSL's Issuance of Debt for the six months ended in Dec. 2023 was $793 Mil.

CSL's Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2023 was $807 Mil.

CSL Issuance of Debt Historical Data

The historical data trend for CSL's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CSL Issuance of Debt Chart

CSL Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Issuance of Debt

Get a 7-Day Free Trial

898.50

1,652.70

38.70

4,092.70

2,539.00

CSL Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Issuance of Debt	Get a 7-Day Free Trial															79.80	4,012.90	2,525.30	13.70	793.00

CSL Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $807 Mil.

CSL Issuance of Debt Related Terms

Thank you for viewing the detailed overview of CSL's Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

CSL (CSLLY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CSL Ltd (OTCPK:CSLLY) » Definitions » Issuance of Debt

Comparable Companies

Traded in Other Exchanges

CMXHF:USA CSJ:Germany CSL:Australia

Address

655 Elizabeth Street, Melbourne, VIC, AUS, 3000

Website

https://www.csl.com

CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world's second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include non-plasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.